The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Related News Articles

Headline
AdventHealth’s Be a Mindleader initiative aims to help children and parents become more comfortable discussing mental health and connect families to counseling…
Headline
Access to quality mental and physical health services can be a complex challenge, but for individuals of color and people with severe or chronic mental…
Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…
Blog
EnglISH¿Qué pasa si una conversación puede cambiar, o incluso salvar, una vida? Esa fue la pregunta que AdventHealth buscó responder, cuando el sistema de…
Blog
ESPAÑOLWhat if one conversation can change, or even save, a life? That was the question AdventHealth sought to answer, as the health system launched a…
Headline
The AHA July 11 released its quarterly Health Care Plan Accountability Update, a roundup of news, letters, statements and other resources covering private…